目的 分析津力達(dá)顆粒聯(lián)合洛塞那肽治療2型糖尿病的臨床療效。方法 選取2022年8月—2023年7月淮南東方醫(yī)院集團(tuán)總醫(yī)院收治的96例2型糖尿病患者，按隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各48例。對照組腹部皮下注射聚乙二醇洛塞那肽注射液，0.1 mg/次，1次/周。治療組在對照組治療基礎(chǔ)上口服津力達(dá)顆粒，1袋/次，3次/d。兩組療程均為8周。觀察兩組的臨床療效，比較治療前后血糖指標(biāo)、全血中性粒細(xì)胞與淋巴細(xì)胞比值（NLR）和血清C反應(yīng)蛋白（CRP）、C肽（CP）水平變化情況。并統(tǒng)計兩組不良反應(yīng)情況。結(jié)果 治療后，治療組總有效率是95.83%，顯著高于對照組的83.33%（P＜0.05）。治療后，兩組餐后2 h血糖（2 h PG）、空腹血糖（FPG）、糖化血紅蛋白（HbA1c）均顯著降低（P＜0.05）；治療后，治療組血糖指標(biāo)低于對照組（P＜0.05）。治療后，兩組全血NLR和血清CRP水平均顯著下降，而血清CP水平均顯著上升（P＜0.05）；治療后，治療組全血NLR和血清CRP低于對照組，CP水平高于對照組（P＜0.05）。治療組和對照組的不良反應(yīng)發(fā)生率分別是6.25%、4.17%，兩組比較差異無統(tǒng)計學(xué)意義。結(jié)論 津力達(dá)顆粒聯(lián)合洛塞那肽治療2型糖尿病具有較佳的安全性及整體療效，能有效降低血糖，減輕機(jī)體炎癥損傷，改善胰島功能。

Objective To analyze the clinical efficacy of Jinlida Granules combined with loxenatide in treatment of type 2 diabetes. Methods A total of 96 patients with type 2 diabetes admitted to Huainan Oriental Hospital Group General Hospital from August 2022 to July 2023 were selected and divided into control group and treatment group according to random number table method, with 48 patients in each group. Patients in the control group were sc administered with Polyethylene Glycol Loxenatide Injection, 0.1 mg/time, once a week. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 1 bag/time, 3 times daily. The treatment course of both groups was 8 weeks. The clinical effects of the two groups were observed, and the changes of blood glucose index, whole blood neutrophil to lymphocyte ratio (NLR), serum C-reactive protein (CRP) and C-peptide (CP) levels before and after treatment were compared. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rate of the treatment group was 95.83%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, 2 h postprandial blood glucose (2 h PG), fasting blood glucose (FPG) and glycosylated hemoglobin (HbA1c) in both groups were significantly decreased (P < 0.05). After treatment, the blood glucose index of the treatment group was lower than that of the control group (P < 0.05). After treatment, whole blood NLR and serum CRP levels were significantly decreased, while serum CP levels were significantly increased in both groups (P < 0.05). After treatment, whole blood NLR and serum CRP in the treatment group were lower than those in the control group, CP level was higher than that in the control group (P < 0.05). The incidence of adverse reactions in the treatment group and the control group was 6.25% and 4.17%, respectively, and there was no statistical significance between the two groups. Conclusion Jinlida Granules combined with loxenatide has better safety and overall efficacy in treatment of type 2 diabetes, and can effectively reduce blood sugar, alleviate inflammatory damage, and improve islet function.

R977

上海市科委“長三角科技創(chuàng)新共同體領(lǐng)域項目合作協(xié)議”項目(22002400600)